Squarepoint
TCRR

Squarepoint’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Squarepoint’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,030
Closed -$84K – 3608
2022
Q2 		$84K Buy
+29,030
New +$71.6K ﹤0.01% 2648
2022
Q1 		– Sell
-41,925
Closed -$195K – 3761
2021
Q4 		$195K Buy
41,925
+25,678
+158% +$161K ﹤0.01% 2718
2021
Q3 		$138K Sell
16,247
-120,655
-88% -$1.7M ﹤0.01% 2604
2021
Q2 		$2.25M Buy
136,902
+50,976
+59% +$1.03M 0.01% 1121
2021
Q1 		$1.9M Buy
85,926
+65,772
+326% +$1.79M 0.01% 1104
2020
Q4 		$623K Buy
+20,154
New +$510K ﹤0.01% 1640
2020
Q1 		– Sell
-13,937
Closed -$199K – 2714
2019
Q4 		$199K Buy
+13,937
New +$215K ﹤0.01% 2230

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's TCRR Position: Q3 2022 in Review

Squarepoint sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 29,030 shares — an estimated $84K sold.

Squarepoint first reported a position in TCRR in Q4 2019 and held it in 7 quarters. The position peaked at $2.25M in Q2 2021. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Squarepoint reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Squarepoint sold 29,030 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $84K.
  • Squarepoint first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • Squarepoint's TCR2 Therapeutics Inc. Common Stock position peaked at $2.25M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.